Post job

Noven main competitors are AstraZeneca, Boehringer Ingelheim, and Allergan plc.

Competitor Summary. See how Noven compares to its main competitors:

  • AstraZeneca has the most employees (76,100).
  • Employees at AstraZeneca earn more than most of the competitors, with an average yearly salary of $112,988.
Work at Noven?
Share your experience

Noven vs competitors

CompanyFounding dateZippia scoreHeadquarters# of LocationsRevenueEmployees
1987
4.6
Miami, FL2$520.0M586
1988
4.8
Aliso Viejo, CA1$115.0M200
1970
4.6
Santa Ana, CA1$300.0M361
Prometheon Pharma
2011
3.3
Gainesville, FL1$160,0003
2015
4.2
Princeton, NJ1$2.2M86
1979
4.2
Ewing, NJ2$184.0M165
1975
4.4
Madison, NJ1$350.0M2,000
1995
4.0
Newark, CA2$342.7M494
1942
4.1
Chesterfield, MO1$91.0M7,500
1986
4.0
Roseland, NJ1$1.2M76
1901
4.3
Kalamazoo, MI1$130.0M350
1953
4.9
Raritan, NJ4$601.4M1,500
1999
4.6
Wilmington, DE8$25.9B76,100
1968
4.2
Rockaway, NJ1$105.1M3,000
1984
4.6
Ridgefield, CT5$17.2B52,391
1997
4.7
Malvern, PA3$2.6B385
1948
4.8
Irvine, CA1$7.2B11,400
1987
4.4
Parsippany-Troy Hills, NJ1$22.0M350
-
4.5
--$6.4B158
1860
4.7
Madison, NJ1$22.4B49,732
2005
4.8
Parsippany-Troy Hills, NJ2$9.0B15,348

Rate Noven's competitiveness in the market.

Zippia waving zebra

Noven salaries vs competitors

Among Noven competitors, employees at AstraZeneca earn the most with an average yearly salary of $112,988.

Compare Noven salaries vs competitors

CompanyAverage salaryHourly salarySalary score
Noven
$69,661$33.49-
Avanir Pharmaceuticals
$65,825$31.65-
FUJIFILM Irvine Scientific
$62,827$30.21-
Prometheon Pharma
$51,894$24.95-
Oyster Point Pharma
$44,982$21.63-
Antares Pharma
$63,492$30.52-

Compare Noven job title salaries vs competitors

CompanyHighest salaryHourly salary
Noven
$71,814$34.53
Allergan plc
$87,301$41.97
Warner Chilcott
$82,903$39.86
Avanir Pharmaceuticals
$79,038$38.00
AstraZeneca
$78,199$37.60
Janssen
$77,543$37.28
Boehringer Ingelheim
$77,221$37.13
FUJIFILM Irvine Scientific
$75,841$36.46
Emisphere Technologies
$75,601$36.35
Wyeth Biopharma
$75,325$36.21
KV Pharmaceutical
$74,773$35.95
Oyster Point Pharma
$74,047$35.60
Prometheon Pharma
$73,960$35.56
Antares Pharma
$73,954$35.55
Depomed
$73,103$35.15
Daiichi Sankyo
$72,144$34.68
Pharmacia
$72,133$34.68
Endo Pharmaceuticals Inc
$71,883$34.56
PDI
$71,789$34.51
Organon
$71,534$34.39

Do you work at Noven?

Does Noven effectively differentiate itself from competitors?

Noven jobs

Noven demographics vs competitors

Compare gender at Noven vs competitors

Job titleMaleFemale
Daiichi Sankyo51%49%
AstraZeneca52%48%
Endo Pharmaceuticals Inc52%48%
Antares Pharma56%44%
Emisphere Technologies62%38%
Noven--

Compare race at Noven vs competitors

CompanyWhiteHispanic or LatinoBlack or African AmericanAsianUnknownDiversity score
71%12%9%5%3%
6.4
60%13%11%12%4%
9.8
60%15%11%10%4%
9.5
60%13%12%11%4%
9.8
42%28%9%16%5%
8.5
52%19%10%15%5%
9.9

Noven and similar companies CEOs

CEOBio
Robert F. Apple
Antares Pharma

Mr. Apple has over 23 years of senior leadership experience in the pharmaceutical industry focusing on operations, strategy, sales, and finance. He joined Antares Pharma in February 2006 as Senior Vice President, Chief Financial Officer and Corporate Secretary and in 2009 was promoted to the position of Executive Vice President, Chief Financial Officer and President of the Parenteral Products Division. In September 2014, Mr. Apple was promoted to the position of Executive Vice President, Chief Operating Officer of the Company. Mr. Apple was promoted to President and Chief Executive Officer in January 2016 and was appointed to the Board of Directors in March 2016. Prior to joining the Company, Mr. Apple served as Chief Operating and Financial Officer at InKine Pharmaceutical Company, Inc. from 2003 to 2005, and Chief Financial Officer from 1997 to 2002. From 1995 to 1997, Mr. Apple was employed by Genaera Corporation, Inc., a biotechnology company, where he held the position of Corporate Controller. From May 1994 until July 1995, Mr. Apple was employed by Liberty Technologies, Inc. as Corporate Controller. Prior to May 1994, Mr. Apple held various positions of increasing responsibility at Arthur Andersen & Company LLP. He holds a B.A. degree in accounting from Temple University.

Dan Peisert
Depomed

Kristin Peck
Alpharma

Pascal Soriot
AstraZeneca

Ken Keller
Daiichi Sankyo

Mark Morse
Pharmacia

Roger Boissonneault
Warner Chilcott

Alan L. Rubino joined the Company as a member of the board of directors in September of 2013. Mr. Rubino has served as President and Chief Executive Officer of Emisphere Technologies, Inc. since September, 2012. Previously, Mr. Rubino served as the CEO and President of New American Therapeutics, Inc., CEO and President of Akrimax Pharmaceuticals, LLC., and President and COO of Pharmos Corporation. Mr. Rubino has continued to expand upon a highly successful and distinguished career that included Hoffmann-La Roche Inc. where he was a member of the U.S. Executive and Operating Committees and a Securities and Exchange Commission (SEC) corporate officer. During his Roche tenure, he held key executive positions in marketing, sales, business operations, supply chain and human resource management, and was assigned executive committee roles in marketing, project management, and globalization. Mr. Rubino also held senior executive positions at PDI, Inc. and Cardinal Health. He holds a BA in economics from Rutgers University with a minor in biology/chemistry and completed post-graduate educational programs at the University of Lausanne and Harvard Business School. Mr. Rubino serves on the Boards of Aastrom Biosciences, Inc. and Genisphere, LLC and is also on the Rutgers University Business School Board of Advisors.”

Brenton L. Saunders
Allergan plc

Noven competitors FAQs

Search for jobs